Elrexfio (elranatamab-bcmm) / Pfizer - LARVOL DELTA

The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3. (PubMed, Hemasphere) - No abstract available

Journal • Hematological Malignancies • Multiple Myeloma • Oncology

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3 (ASH 2025) - P2 | "Furthermore, these data support thefeasibility of dose interruptions to manage adverse events and allow for treatment breaks withoutcompromising the efficacy of ELRA. Studies evaluating the possibility of restarting ELRA upon signs ofdisease progression are warranted."

Retrospective data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Respiratory Diseases • Septic Shock

Indirect comparison of linvoseltamab (LINVO) versus elranatamab (ELRA) for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) (DKK 2026) - No abstract available

Hematological Malignancies • Multiple Myeloma

Progressive multifocal leukoencephalopathy associated with elranatamab therapy in relapsed/refractory multiple myeloma. (PubMed, J Oncol Pharm Pract) - "Despite treatment with intravenous immunoglobulin, mirtazapine, and compassionate-use nivolumab, her neurological status progressively worsened, necessitating intubation and intensive care management.DiscussionThis case suggests a probable association between elranatamab therapy and JC virus reactivation leading to PML. Early neuroimaging and cerebrospinal fluid JC virus testing, combined with proactive immunoglobulin replacement and systematic pharmacovigilance, are essential for timely diagnosis and improved outcomes. Overall, this case highlights the need for early JC virus monitoring and awareness of delayed neuroinfectious complications associated with BCMA-targeted immunotherapies."

Journal • CNS Disorders • Critical care • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Rare Diseases

Preemptive Tocilizumab with Bispecific Antibodies in Relapsed-Refractory Multiple Myeloma: A Case Series (TCT-ASTCT-CIBMTR 2026) - "Teclistamab (Tec), Talquetamab (Tal), and Elranatamab (Elra) are bispecific antibodies (BsAbs) approved for relapsed-refractory Multiple Myeloma (RRMM) which target CD3 on T- cells and either BCMA or GPRC5D, depending on the BsAb...The only incident of CRS occurred with a single patient who developed grade 1 CRS on C1D3 which resolved after one dose dexamethasone 10 mg...Supportive care was given during treatment including filgrastim to maintain absolute neutrophil 1.00 K/mcl, epoetin alfa to maintain hemoglobin above 10g/dl, and romiplostim to maintain platelets above 50 K/mcl...3. Evaluate the potential role and clinical impact of preemptive tocilizumab administration in reducing the incidence and severity of CRS without compromising therapeutic response in patients receiving bispecific antibodies."

Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • IL6

Beta-Blocker Exposure and Immune Effector Toxicity after Myeloma Bispecific Antibodies: A Propensity-Matched Trinetx Study (TCT-ASTCT-CIBMTR 2026) - " TriNetX Global Health Research Network was queried for adults with MM initiating commercial BsAbs (teclistamab, talquetamab, or elranatamab; index = first BsAb). In a propensity-matched real-world MM cohort initiating BsAbs, baseline BB exposure was not associated with clinically significant CRS (0–14 or 0–30 days), tocilizumab use, or 1-year OS. These data suggest concomitant BB therapy does not meaningfully alter early immune effector toxicity signals during BsAb initiation."

Late-breaking abstract • Asthma • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Heart Failure • Hematological Malignancies • Hypertension • Immune Modulation • Immunology • Inflammation • Metabolic Disorders • Multiple Myeloma • Myocardial Infarction • Nephrology • Renal Disease • Respiratory Diseases

Bispecific Therapy in Refractory Multiple Myeloma in the Octogenarian Population (TCT-ASTCT-CIBMTR 2026) - "Individuals who were treated with teclistimab were more likely to be rehospitalized compared to those who received elranatamab or talquetamab therapy (83.3%, n=5 vs. 16.7%, n=1; p=0.03, respectively). Elevated beta-2 microglobulin levels in the octogenarian population following bispecific therapy induction may be used as a poor prognostic marker, with significantly higher levels in those who passed away. It may be used to guide future therapy and manage expectations. Additionally, the comparison of different bispecific therapies and re-hospitalization requires further investigation."

Clinical • Hematological Malignancies • Multiple Myeloma • B2M

Real-World Outcomes of Heavily Pretreated Relapsed Refractory Multiple Myeloma Patients Treated with Bispecific Antibodies (TCT-ASTCT-CIBMTR 2026) - "INTRODUCTION 4 Bispecific antibodies (BsAb): Teclistamab (Tec), Elranatamab (Elran), Talquetamab (Tal) & Linvoseltamab are approved for relapsed refractory multiple myeloma (RRMM) after ≥4 lines of therapy (LOT), with impressive overall response rates (ORR) and progression free survival (PFS). 3. To compare OS between early responders (those achieving partial response, VGPR, complete remission within ≤1 month of therapy initiation) and patients with stable or progressive disease at 2 month post bispecific antibody"

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

30-Day Non-Relapse Mortality In Multiple Myeloma Patients Treated with Bispecific T-cell Engagers: A Faers Analysis (TCT-ASTCT-CIBMTR 2026) - "Agents such as teclistamab, elranatamab, and talquetamab have demonstrated efficacy in heavily pretreated patients. Real-world post-marketing data indicate that approximately 4% of MM patients treated with bispecific T- cell engagers experience non-relapse mortality within 30 days of therapy initiation. Most deaths were linked to immunotherapy-associated toxicities rather than disease progression. These findings underscore the importance of vigilant early-phase monitoring, aggressive management of CRS and infections, and proactive supportive care to mitigate treatment-related mortality during the initial month of BiTE therapy."

Clinical • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Pneumonia • Respiratory Diseases • Septic Shock

Elranatamab treatment in a refractory multiple myeloma patient on maintenance hemodialysis (PubMed, Rinsho Ketsueki) - "Although induction therapy with bortezomib and dexamethasone achieved a hematological response, he remained dependent on hemodialysis. Extramedullary lesions developed in April 2024 during fifth-line treatment with daratumumab, pomalidomide, and dexamethasone...Although data on bispecific antibodies in patients on hemodialysis are limited, our case demonstrates that elranatamab can be administered safely and effectively in this population. Consequently, elranatamab could be a feasible and effective therapeutic option for patients with multiple myeloma on hemodialysis."

Journal • Acute Kidney Injury • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology • Renal Disease

Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. (ASCO 2023) - P1b/2, P2b, P3 | " We analyzed the effectiveness of non-cellular αBCMA (NCA) therapies in pts with MM treated in 4 clinical studies (STORM [NCT02336815]; STOMP [NCT02343042]; BOSTON [NCT03110562], XPORT-MM-028 [NCT04414475]) with selinexor + dexamethasone (Xd), with or without PIs, IMiDs, or αCD38 mAbs, followed by therapy with NCA...Thirty-seven pts (median age: 68, range: 40-87) received NCA therapy at any time following a selinexor regimen (Xd, n = 12; Xd + bortezomib, n = 9; Xd + pomalidomide, n = 6; Xd + daratumumab, n = 3; Xd + carfilzomib, n = 5; Xd + ixazomib, n = 2). NCAs included the ADC belantamab mafodotin (n = 28), the BiS teclistamab (n = 2), SEA-BCMA (n = 2), AMG 701 (n = 1), elranatamab (n = 1), MEDI2228 (n = 1), and investigational (n = 3; 2 had αBCMA bispecific antibodies and 1 had αBCMA BITE) (1 pt received 2 NCAs, belantamab and teclistamab)... In this cohort of heavily-pretreated pts with MM who received a selinexor regimen prior to NCA, overall..."

Hematological Malignancies • Immune Modulation • Multiple Myeloma • Oncology

"Users of the Monitored Drug Registries are informed…ELREFXIO registry is available for the following therapeutic indication: ELREXFIO as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma…" [Google translation] (Italian Medicines Agency)

Reimbursement • Hematological Malignancies • Multiple Myeloma • Oncology

Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial (ASH 2025) - P1, P2 | "The study continuesenrolling and will explore ELRA + IBER in a larger group of pts with RRMM. Results from a longer follow-up will be presented."

Clinical • Combination therapy • P1 data • Anorexia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Pfizer

New trial • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status? (PubMed, Target Oncol) - "This has resulted in European Medicines Agency and US Food and Drug Administration approval of agents targeting the B-cell maturation antigen: antibody-drug conjugate belantamab mafodotin (belantamab), bispecific T-cell engaging antibodies teclistamab, elranatamab and linvoseltamab, and chimeric antigen receptor T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). Talquetamab, a bispecific T-cell engaging antibody targeting G protein coupled receptor family C group 5 member D has also been approved by the European Medicines Agency and Food and Drug Administration. With increasing availability of these agents, knowledge on the efficacy and safety of these novel treatments will be essential for future multiple myeloma care. In this narrative review, we discuss the pivotal trials, current real-world evidence and recent insights in the mechanisms of resistance of antibody-drug conjugates, bispecific T-cell engaging antibodies and..."

Journal • Review • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" (clinicaltrials.gov) - P2 | N=34 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial. (PubMed, J Hematol Oncol) - "All patients received BCMA/GPRC5D bispecific CAR T-cell therapy after bridging therapy with localized radiotherapy or Elranatamab...Median OS and PFS were not reached. Collectively, these findings highlight a potential therapeutic strategy involving BCMA/GPRC5D dual-targeted CAR T-cell therapy for patients with aggressive forms of multiple myeloma, particularly those with extramedullary disease, and support the need for further exploration and validation in larger, multi-center clinical studies."

Journal • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Leukopenia • Multiple Myeloma • Oncology • Thrombocytopenia

Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report. (PubMed, Int J Hematol) - "JTT may enhance the efficacy of T cell-redirecting immunotherapies in RRMM by promoting cytotoxic T cell expansion. These findings warrant further investigation into the use of JTT as an adjunct to improve outcomes in patients with EMD."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • CD4

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: C4 Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1 (ASH 2025) - P1/2 | "Participants will receive MEZI (without ELRA) until confirmedPD by investigator, unacceptable toxicity as assessed by the investigator and/or withdrawal of consent.Key inclusion criteria include 2 prior lines of antimyeloma therapy including lenalidomide and at least 1proteasome inhibitor, age ≥19 years, diagnosis of MM according to IMWG criteria, an ECOG performancestatus ≤2, and measurable disease. In patients with R/R MM, initial results suggest that the combination of MEZI + ELRA isclinically feasible and show therapeutic potential."

Clinical • IO biomarker • P1/2 data • Acute Kidney Injury • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases • IKZF1

Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma. (PubMed, J Clin Exp Hematop) - "Dexamethasone administration improved the ocular symptoms. Differentiating pseudoprogression from true progression is clinically important, as misinterpretation may lead to premature discontinuation of effective therapy. Careful clinical evaluation, integration of imaging findings, and histopathological confirmation (whenever feasible) are essential for the appropriate management of such cases."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Ophthalmology

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma (ASH 2022) - P1, P3 | "Elranatamab induced durable clinical and molecular responses for pts with relapsed or refractory MM. The ORR was 64% with more than half of these pts (38%) achieving CR or better, and 100% of evaluable pts achieved MRD negativity. Together with emerging data from pivotal studies MagnetisMM-3 (NCT0469359) and MagnetisMM-5 (NCT05020236), these results support further development of elranatamab for patients with MM."

Clinical • IO biomarker • Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Transplantation

Dramatic Response to Elranatamab in a Patient with Large Plasmacytomas. (PubMed, Turk J Haematol) - No abstract available

Journal • Oncology • Plasmacytoma

Efficacy and Safety of Less Frequent Dosing With Elranatamab (ELRA) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): A US Subgroup Analysis from MagnetisMM-3 (IMS 2025) - P2 | "Pts with RRMM in MagnetisMM-3 Cohort A, including the US subgroup, were heavily pretreated. Consistent with overall Cohort A data, ELRA induced deep, durable responses in the US subgroup, with a mPFS of 27.3 mo. CRS was G1 and G2 only."

Clinical • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Pneumonia • Respiratory Diseases

Elranatamab in Combination With Daratumumab and Lenalidomide (EDR) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results from MagnetisMM-6 Part 1 (IMS 2025) - P3 | "MagnetisMM-6 (NCT05623020) is a phase 3, open-label, randomized study evaluating the efficacy and safety of ELRA in combination with lenalidomide (R) ± daratumumab (DARA) (EDR or ER) vs DARA + R + dexamethasone (DRd) in pts with transplant-ineligible (TI) NDMM. In pts with TI NDMM, EDR demonstrated a manageable safety profile consistent with the known toxicities of components. High response rates and early responses were observed, with responses expected to deepen with longer follow-up. Enrollment in dose level H evaluating the ER combination is ongoing."

Clinical • Combination therapy • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Pneumonia • Respiratory Diseases • Transplantation